India grants patent for PlantForm antibody technology
GUELPH, Ont., Feb. 14, 2019—PlantForm Corporation has been granted a patent by the Indian Patent Office for its innovative method for improving therapeutic efficacy of antibody fragments, such as VHH or Fab, by binding with full-length antibodies to enhance circulatory residence time or to provide specific Fc-related effector function.
India Patent No. 305059, titled “An Antibody Fragment Linked To An Epitope Complexed With An Antibody That Binds To An Epitope,” is part of a group of patents already granted in Canada and the United States for PlantForm’s plant-produced antidote to cobra toxin, and in the European Union for improving the therapeutic efficacy of antibody fragments.
The antibody fragments and cognate antibody are produced using PlantForm’s proprietary tobacco-plant-based platform for rapid, low-cost development of antibody and protein drugs.
“The issuing of this patent confirms the utility of vivoXPRESS® for low-cost drug production in India’s important and growing pharmaceutical market,” said Dr. Don Stewart, PlantForm’s President and CEO. “PlantForm recently announced the grant of a different patent for an antidote to cobra snakebites. PlantForm is excited to further develop partnering discussions for both biosimilar and antivenom drugs for the Indian market.”
PlantForm licenses the platform technology from the University of Guelph, where it was invented by Dr. J. Christopher Hall, the company’s Chief Scientific Officer.
PlantForm has an expanding portfolio of patents in seven families to protect both the core platform technology and products in development.
About PlantForm Corporation (www.plantformcorp.com)
PlantForm Corporation is a biopharmaceutical company focused on the rapid development and production of specialty antibody and protein drugs using the company’s proprietary vivoXPRESS® platform
. The plant-based vivo
system makes it easier, faster and less expensive to produce approved biologic drugs for novel indications and new markets. The company’s pipeline includes trastuzumab for a novel indication in nerve regeneration; a biosimilar version of Lucentis®; biosimilar adalimumab (Humira®) through our PlantPraxis joint venture in Brazil; other biobetter drugs for niche indications; and medical countermeasures to terrorism threats such as ricin and sarin through PlantForm subsidiary AntoXa Corporation. Learn more.
For more information, please contact:
Join us online!
Get regular updates on our activities and industry news by following PlantForm on Twitter, LinkedIn and Facebook: